About T23 Biopharmaceutical

About company

T23 is pre-clinical and clinical stage biopharmaceutical Company. Located at Torrey Pines Investment campus in San Diego, CA it is focused on development of novel targeted immunotherapies for treatment of patients with cancer and autoimmune disease. T101, their candidate conjugate of siglec ligand and nanosomal formulation is currently in pre-clinical development with other conjugates in discovery.